Trending Topics in Gastroenterology
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
Explore current gastroenterology questions, clinical answers, and emerging research by topic.
Introduction: Metabolic dysfunction-associated steatohepatitis (MASH) remains a leading cause of cirrhosis, liver failure, and hepatocellular carcinoma, with limited treatment options. This study evaluated DT-109, a novel glycine-based tripeptide,...
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is closely linked to obesity, diabetes, and cardiovascular disease. While both tirzepatide and SGLT2 inhibitors improve metabolic health, comparative real-world data...
Introduction: GLP-1 receptor agonists (GLP-1RAs) have revolutionized obesity treatment, producing substantial weight loss and cardiometabolic benefits. However, many patients discontinue therapy because of cost, adverse effects, or limited...
Introduction: The treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) is evolving rapidly with the emergence of incretin-based therapies. Beyond improving weight and glycemic control, these agents are showing...
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) are now recognized as systemic metabolic diseases rather than isolated liver disorders. This review integrates current...
Integrated single-cell and single-nucleus RNA sequencing identified a distinct hepatic stellate cell population associated with MASH-related fibrosis. AREL1 emerged as a characteristic gene of this fibrogenic stellate-cell population...
This review proposes a processing-centred gut–liver–brain axis, positioning MASLD as a metabolic amplifier between ultra-processed food exposure and cognitive decline. Ultra-processed foods are not simply high in sugar,...
Introduction: Metabolic dysfunction–associated steatotic liver disease (MASLD) has emerged as one of the most prevalent chronic liver diseases worldwide, affecting nearly one-third of adults and a majority of...
Introduction: Metabolic dysfunction-associated steatotic liver disease (MASLD) is traditionally linked to obesity, but an increasing number of patients develop significant hepatic steatosis despite having a normal body mass...
Resmetirom is the first FDA-approved therapy for patients with MASH/MASLD and stage F2–F3 fibrosis, creating an urgent need for reliable noninvasive methods to identify treatment candidates. This study...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.